An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Inclusion Criteria: * Gradual and progressive change in the participant's memory function over more than 6 months, reported by participant and study partner * Mini-Mental State Examination score of 20-30 inclusive at screening * Objective impairment in memory as evaluated by memory test performed at screening * For a diagnosis of mild Alzheimer's Disease (AD), participant meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable AD * For a diagnosis of MCI due to AD, participant meets NIA-AA criteria for MCI due to AD Exclusion Criteria: * Significant neurological disease affecting the central nervous system, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson´s disease, or epilepsy or recurrent seizures * History of clinically evident stroke, or multiple strokes based on history or imaging results * History of clinically important carotid or vertebrobasilar stenosis or plaque * History of multiple concussions with sustained cognitive complaints or objective change in neuropsychological function in the last 5 years * Participants with a current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of Major Depressive Disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation …